The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma

Penchala, Sujan Dilly, Fawcett, Sandra, Else, Laura, Egan, Deirdre, Amara, Alieu ORCID: 0000-0002-1137-2948, Elliot, Emilie, Challenger, Elizabeth ORCID: 0000-0002-8978-6067, Back, David, Boffito, Marta and Khoo, Saye ORCID: 0000-0002-2769-0967 (2016) The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1027. pp. 174-180.

Text DTG, EVG, COBI in Plasma_R1.docx - Author Accepted Manuscript Download (556kB)

Abstract

Dolutegravir and Elvitegravir belongs to a class of integrase inhibitors which has recently been approved by the FDA for the treatment of HIV-infection. Elvitegravir and its co-administered booster drug, Cobicistat, has shown the potential to be a candidate for a one pill once a day regimen and is currently a component of many clinical trials. A sensitive LC-MS/MS method has been developed and validated for the simultaneous determination of these three drugs in human plasma. A liquid- liquid extraction was used as a sample preparation technique using 100μL of plasma. The method was validated from 10 to 4000ng/mL for Dolutegravir, Elvitegravir and Cobicistat. Chromatography was performed on XBridge C18 2.1mm×50mm column, using an 80:20 methanol/water mobile phase containing 0.1% formic acid on a gradient program. This method was successfully applied for ongoing clinical trials.

Item Type:	Article
Uncontrolled Keywords:	Dolutegravir, Elvitegravir, Cobicistat, LC-MS/MS, Method validation
Depositing User:	Symplectic Admin
Date Deposited:	09 Sep 2016 11:05
Last Modified:	19 Jan 2023 07:30
DOI:	10.1016/j.jchromb.2016.05.040
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3003183